Attovia Therapeutics (ATTO), a Phase 1 biotech developing drugs to treat chronic itching and IBD, priced its IPO at $17.00 – the top of its range, as expected – and sold 17 million shares – matching the IPO’s upsized terms disclosed this morning – to raise $289 million on Tuesday night, Aug. 4, 2026. At pricing, Attovia had a market cap of $731.49 million.
Attovia Therapeutics’ stock (ATTO) jumped to $21.00 – up $4.00 from its IPO price for an opening gain of 23.53 percent – in its NASDAQ debut at 12:18 p.m. EDT on Wednesday (Aug. 5, 2026). Volume on the opening trade was 672,648 shares, according to NASDAQ.
By around 1:20 p.m. EDT, Attovia’s stock had extended its gains – trading at $22.05 – up $5.05 for a 29.7 percent gain from its IPO price – on NASDAQ volume of about 2.7 million shares.
At Wednesday’s closing bell, Attovia’s stock was at $21.90 – up $4.90 from its IPO price for a gain of 28.82 percent on Aug. 5, 2026, its first day of NASDAQ trading. Volume: About 4.8 million shares.
Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets and LifeSci Capital were the joint book-runners.
Attovia, based in San Carlos, California, plans to start Phase 1 clinical trials next year for its three drug candidates, the prospectus said.
Alamar Biosciences (ALMR), which went public in mid-April, is one of Attovia’s founding shareholders. Goldman Sachs Alternatives is a principal shareholder as well.
Financial Snapshot: Net loss of $64.13 million on collaboration revenue of $1.35 million for the 12 months that ended on March 31,2026
(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.
Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and the rating is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.